# ITIL-168 in Advanced Melanoma

Source: https://onco.cc/trials/nct05050006/  
OnCo record `nct05050006` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ITIL-168 run by Instil Bio, terminated.

## Summary

ITIL-168 in Advanced Melanoma is a phase 2 interventional study registered as NCT05050006 by Instil Bio, with 29 participants enrolled, started 2021-10-07. Conditions recorded: Advanced Cutaneous Melanoma. Interventions recorded: ITIL-168.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05050006
- Phase: 2
- Setting: A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
- Sponsor: Instil Bio
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT05050006: https://clinicaltrials.gov/study/NCT05050006

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [ITIL-168](https://onco.cc/drugs/itil-168/)
- companies: [Instil Bio](https://onco.cc/companies/instil-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct05050006.json